These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 15561883)

  • 21. Calcineurin inhibition or mutation enhances cell wall inhibitors against Aspergillus fumigatus.
    Steinbach WJ; Cramer RA; Perfect BZ; Henn C; Nielsen K; Heitman J; Perfect JR
    Antimicrob Agents Chemother; 2007 Aug; 51(8):2979-81. PubMed ID: 17502415
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro activity of calcineurin and heat shock protein 90 Inhibitors against Aspergillus fumigatus azole- and echinocandin-resistant strains.
    Lamoth F; Juvvadi PR; Gehrke C; Steinbach WJ
    Antimicrob Agents Chemother; 2013 Feb; 57(2):1035-9. PubMed ID: 23165466
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Assessing the antifungal activity, pharmacokinetics, and tissue distribution of amphotericin B following the administration of Abelcet and AmBisome in combination with caspofungin to rats infected with Aspergillus fumigatus.
    Wasan KM; Sivak O; Rosland M; Risovic V; Bartlett K
    J Pharm Sci; 2007 Jul; 96(7):1737-47. PubMed ID: 17080414
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Update on antifungal drug resistance mechanisms of Aspergillus fumigatus.
    Chamilos G; Kontoyiannis DP
    Drug Resist Updat; 2005 Dec; 8(6):344-58. PubMed ID: 16488654
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of efficacy of antifungals against Aspergillus fumigatus: value of real-time bioluminescence imaging.
    Galiger C; Brock M; Jouvion G; Savers A; Parlato M; Ibrahim-Granet O
    Antimicrob Agents Chemother; 2013 Jul; 57(7):3046-59. PubMed ID: 23587947
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro activities of 10 combinations of antifungal agents against the multiresistant pathogen Scopulariopsis brevicaulis.
    Cuenca-Estrella M; Gomez-Lopez A; Buitrago MJ; Mellado E; Garcia-Effron G; Rodriguez-Tudela JL
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2248-50. PubMed ID: 16723597
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Voriconazole inhibits fungal growth without impairing antigen presentation or T-cell activation.
    Van Epps HL; Feldmesser M; Pamer EG
    Antimicrob Agents Chemother; 2003 Jun; 47(6):1818-23. PubMed ID: 12760853
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis.
    Pavie J; Lacroix C; Hermoso DG; Robin M; Ferry C; Bergeron A; Feuilhade M; Dromer F; Gluckman E; Molina JM; Ribaud P
    J Clin Microbiol; 2005 Sep; 43(9):4902-4. PubMed ID: 16145172
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Flow cytometry antifungal susceptibility testing of Aspergillus fumigatus and comparison of mode of action of voriconazole vis-à-vis amphotericin B and itraconazole.
    Ramani R; Gangwar M; Chaturvedi V
    Antimicrob Agents Chemother; 2003 Nov; 47(11):3627-9. PubMed ID: 14576132
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of Sensititre YeastOne with the NCCLS M38-A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J; Peláez T; Alcalá L; Bouza E
    Diagn Microbiol Infect Dis; 2006 Sep; 56(1):53-5. PubMed ID: 16650953
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species.
    Kontoyiannis DP; Lewis RE; Osherov N; Albert ND; May GS
    J Antimicrob Chemother; 2003 Feb; 51(2):313-6. PubMed ID: 12562696
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Correlation between the E test and the CLSI M-38 A microdilution method to determine the activity of amphotericin B, voriconazole, and itraconazole against clinical isolates of Aspergillus fumigatus.
    Guinea J; Peláez T; Alcalá L; Bouza E
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3):273-6. PubMed ID: 17141455
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expression turnover profiling to monitor the antifungal activities of amphotericin B, voriconazole, and micafungin against Aspergillus fumigatus.
    Zhao Y; Paderu P; Park S; Dukhan A; Senter M; Perlin DS
    Antimicrob Agents Chemother; 2012 May; 56(5):2770-2. PubMed ID: 22314535
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effect of voriconazole combined with micafungin against Candida, Aspergillus, and Scedosporium spp. and Fusarium solani.
    Heyn K; Tredup A; Salvenmoser S; Müller FM
    Antimicrob Agents Chemother; 2005 Dec; 49(12):5157-9. PubMed ID: 16304192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp.
    Perea S; Gonzalez G; Fothergill AW; Kirkpatrick WR; Rinaldi MG; Patterson TF
    Antimicrob Agents Chemother; 2002 Sep; 46(9):3039-41. PubMed ID: 12183266
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interaction of the echinocandin caspofungin with amphotericin B or voriconazole against Aspergillus biofilms in vitro.
    Liu W; Li L; Sun Y; Chen W; Wan Z; Li R; Liu W
    Antimicrob Agents Chemother; 2012 Dec; 56(12):6414-6. PubMed ID: 23027186
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In vitro antifungal activities of anidulafungin and micafungin, licensed agents and the investigational triazole posaconazole as determined by NCCLS methods for 12,052 fungal isolates: review of the literature.
    Espinel-Ingroff A
    Rev Iberoam Micol; 2003 Dec; 20(4):121-36. PubMed ID: 15456349
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characterization of the FKBP12-Encoding Genes in Aspergillus fumigatus.
    Falloon K; Juvvadi PR; Richards AD; Vargas-Muñiz JM; Renshaw H; Steinbach WJ
    PLoS One; 2015; 10(9):e0137869. PubMed ID: 26366742
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical outcomes of lung-transplant recipients treated by voriconazole and caspofungin combination in aspergillosis.
    Thomas A; Korb V; Guillemain R; Caruba T; Boussaud V; Billaud E; Prognon P; Begué D; Sabatier B
    J Clin Pharm Ther; 2010 Feb; 35(1):49-53. PubMed ID: 20175811
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antimicrobial susceptibility of Fusarium, Aspergillus, and other filamentous fungi isolated from keratitis.
    Lalitha P; Shapiro BL; Srinivasan M; Prajna NV; Acharya NR; Fothergill AW; Ruiz J; Chidambaram JD; Maxey KJ; Hong KC; McLeod SD; Lietman TM
    Arch Ophthalmol; 2007 Jun; 125(6):789-93. PubMed ID: 17562990
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.